Reply to the letter to the editor 'patients' preference and informed consent' by Pumo et al

Affiliations

¹ Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France. Electronic address: xavier.pivot@univ-fcomte.fr.
² F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Free article

Comment

X Pivot et al. Ann Oncol. 2015 Jun.

Free article

. 2015 Jun;26(6):1269-1270.

doi: 10.1093/annonc/mdv145. Epub 2015 Mar 18.

¹ Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France. Electronic address: xavier.pivot@univ-fcomte.fr.
² F. Hoffmann-La Roche Ltd, Basel, Switzerland.

No abstract available

Comment on

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Pivot X, et al. Ann Oncol. 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdu364. Epub 2014 Jul 28. Ann Oncol. 2014. PMID: 25070545 Clinical Trial.
Patients' preference and informed consent.
Pumo V, Di Mari A, Rametta Giuliano S, Bordonaro S, Lanteri E, Tralongo P. Pumo V, et al. Ann Oncol. 2015 Jun;26(6):1269. doi: 10.1093/annonc/mdv143. Epub 2015 Mar 18. Ann Oncol. 2015. PMID: 25787921 No abstract available.